Bristol-Myers Squibb | Patient Daily

Bristol-Myers Squibb

Press release submission | Aug 9, 2020

BRISTOL-MYERS SQUIBB: Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

Press release submission | Feb 16, 2020

BRISTOL-MYERS SQUIBB: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Carol Ostrow | Dec 27, 2017

Restrictions on Opdivo combination trials for multiple myeloma treatment lifted by FDA

Carol Ostrow | Dec 27, 2017

Seattle Genetics, Bristol-Myers Squibb report Hodgkin treatment study interim results

Carol Ostrow | Dec 26, 2017

Bristol-Myers Squibb, Pfizer, others aim to raise awareness of stroke risk in atrial fibrillation patients

Robert Hadley | Nov 8, 2017

Europe agency approves expanded use of Bristol-Myers Squibb’s Opdivo to treat advanced melanoma

Carol Ostrow | Oct 14, 2017

Opdivo approved for treating certain liver cancer patients

Carol Ostrow | Oct 1, 2017

AbbVie, Bristol-Myers Squibb collaborate on anti-cancer regimen to target lung tumors

Trending

Patient Daily | Sep 17, 2025

Patients Come First spokesperson: Drug ads 'are putting lives at risk by encouraging people to abandon essential treatments'

Patient Daily | Sep 17, 2025

PhRMA’s Senior Director on 340B: 'State and federal investigations have shown 340B is often exploited for profit'

Patient Daily | Sep 19, 2025

ENT specialist on ongoing chronic sinus cases: ‘Some of it could be incomplete surgery’

+ Pharmaceuticals

Patient Daily | Sep 23, 2025

Wall Street Journal editorial board alleges hospitals misuse 340B program